Skip to main content
Log in

Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose in oncology

Part II. The clinical value in detecting and staging primary tumours

  • REVIEW
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

The tumoral uptake of 2-[18F]fluoro-2-deoxy-D-glucose (18FdGlc) is based upon enhanced glycolysis. Positron-emission tomography (PET) using 18FdGlc provides the physiological and metabolic information. 18FdGlc PET has been used successfully for assessing primary tumours and metastases, prognosis, and planning and for monitoring tumour therapy as well as for early detection of recurrent tumour growth. This review summarises the uptake mechanism of 18FdGlc in benign and malignant lesions, its relation to histolopathology, and its clinical value for detecting and staging primary tumours.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: 7 December 1999 / Accepted: 1 February 2000

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ak, I., Stokkel, M. & Pauwels, E. Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose in oncology . J Cancer Res Clin Oncol 126, 560–574 (2000). https://doi.org/10.1007/PL00008466

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/PL00008466

Navigation